Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
dnGEgLqbNu9RgZgB
